Matthew Maxwell Donley is COO at Aurinia Pharmaceuticals Inc. (AUPH). They have made 5 open-market trades across 1 company since 2021, most recently 2026-03-02.
CIK 0001636642
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $146K since 2021, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AUPH | SELL | 2025-03-03 | 2025-03-04 | $7.95 | $1.5M | +0.7% | -0.6% | -1.7% |
| AUPH | SELL | 2024-03-06 | 2024-03-07 | $5.51 | $448K | -5.1% | -8.8% | +0.0% |
| AUPH | BUY | 2022-11-21 | 2022-11-23 | $4.66 | $47K | -2.8% | -7.9% | +58.1% |
| AUPH | SELL | 2022-03-02 | 2022-03-04 | $12.01 | $37K | +2.7% | +15.7% | +2.9% |
| AUPH | BUY | 2021-05-11 | 2021-05-12 | $10.07 | $100K | +8.7% | +10.5% | +30.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.